Last reviewed · How we verify
Specific anti-SARS-CoV-2 antibodies — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Specific anti-SARS-CoV-2 antibodies (Specific anti-SARS-CoV-2 antibodies) — Egyptian Center for Research and Regenerative Medicine.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Specific anti-SARS-CoV-2 antibodies TARGET | Specific anti-SARS-CoV-2 antibodies | Egyptian Center for Research and Regenerative Medicine | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Specific anti-SARS-CoV-2 antibodies CI watch — RSS
- Specific anti-SARS-CoV-2 antibodies CI watch — Atom
- Specific anti-SARS-CoV-2 antibodies CI watch — JSON
- Specific anti-SARS-CoV-2 antibodies alone — RSS
Cite this brief
Drug Landscape (2026). Specific anti-SARS-CoV-2 antibodies — Competitive Intelligence Brief. https://druglandscape.com/ci/specific-anti-sars-cov-2-antibodies. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab